Invictus RG’s Theravance Biopharma TBPH Stock Holding History

Invictus RG’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-32	Closed	-$1K	–	824
2016 Q4	$1K	Buy	+32	New	+$993	﹤0.01%	608

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Invictus RG's TBPH Position: Q1 2017 in Review

Invictus RG sold out of Theravance Biopharma (TBPH) in Q1 2017, closing a stake of 32 shares — an estimated $1K sold.

Invictus RG first reported a position in TBPH in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 92 funds tracked by Wall St. Rank hold TBPH as of Q1 2017.

Invictus RG reported no remaining Theravance Biopharma position as of Q1 2017 after selling out during the quarter.
Invictus RG sold 32 Theravance Biopharma shares in Q1 2017, an estimated $1K.
Invictus RG first reported a position in Theravance Biopharma in Q4 2016 and held it in 1 quarter.
Invictus RG's Theravance Biopharma position peaked at $1K in Q4 2016.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2017.

Based on Invictus RG's 13F filing for Q1 2017, filed 12 May 2017.